Investors’ Patience Is Being Tested Right Now By Caribou Biosciences Inc (NASDAQ: CRBU)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Caribou Biosciences Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Caribou Biosciences Inc is $597.79M. A total of 1.17 million shares were traded on the day, compared to an average of 1.76M shares.

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, CRBU has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 2 BUYs and 0 SELLs from insiders. Insiders purchased 20,000 shares during that period but sold 0.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CRBU has a high of $8.59 and a low of $3.44.

As of this writing, CRBU has an earnings estimate of $Caribou Biosciences, Inc. per share for the current quarter. EPS was calculated based on a consensus of Corbus Pharmaceuticals Holdings estimates, with a high estimate of $Community Bank System, Inc. per share and a lower estimate of $Corebridge Financial Inc.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRBU is Buy with a score of 4.67.

Most Popular

Related Posts